156 related articles for article (PubMed ID: 37837921)
1. Long-term comparisons of the durability of 6 months versus 12 months antiviral therapy for hepatitis B after chemotherapy cessation.
Yang SY; Hu TH; Chou YP; Kuo YH; Tsai MC; Chang KC; Yen YH; Tseng PL
J Infect Public Health; 2023 Nov; 16(11):1852-1859. PubMed ID: 37837921
[TBL] [Abstract][Full Text] [Related]
2. Pretreatment serum HBsAg-to-HBV DNA ratio predicts a virologic response to entecavir in chronic hepatitis B.
Song JC; Min BY; Kim JW; Kim JY; Kim YM; Shin CM; Lee SH; Hwang JH; Jeong SH; Kim N; Lee DH
Korean J Hepatol; 2011 Dec; 17(4):268-73. PubMed ID: 22310791
[TBL] [Abstract][Full Text] [Related]
3. Incidence and Factors Associated With HBV Relapse After Cessation of Entecavir or Tenofovir in Patients With HBsAg Below 100 IU/mL.
Tseng TN; Hu TH; Wang JH; Kuo YH; Hung CH; Lu SN; Jeng WJ; Chen CH
Clin Gastroenterol Hepatol; 2020 Nov; 18(12):2803-2812.e2. PubMed ID: 32360818
[TBL] [Abstract][Full Text] [Related]
4. Serum Level of Antibodies Against Hepatitis B Core Protein Is Associated With Clinical Relapse After Discontinuation of Nucleos(t)ide Analogue Therapy.
Chi H; Li Z; Hansen BE; Yu T; Zhang X; Sun J; Hou J; Janssen HLA; Peng J
Clin Gastroenterol Hepatol; 2019 Jan; 17(1):182-191.e1. PubMed ID: 29902645
[TBL] [Abstract][Full Text] [Related]
5. Combined baseline HBcrAg and end-of-treatment HBsAg predict HBV relapse after entecavir or tenofovir cessation.
Tseng TN; Jeng WJ; Hu TH; Wang JH; Hung CH; Lu SN; Chen CH
J Antimicrob Chemother; 2023 Feb; 78(2):436-439. PubMed ID: 36478233
[TBL] [Abstract][Full Text] [Related]
6. Role of hepatitis B surface antigen in hepatitis B virus relapse after entecavir or tenofovir prophylaxis in patients undergoing cancer chemotherapy.
Kuo MT; Tseng PL; Chou YP; Chang KC; Tsai MC; Kuo YH; Hu TH; Hung CH; Wang JH; Lu SN; Chen CH
J Gastroenterol Hepatol; 2018 Oct; 33(10):1766-1772. PubMed ID: 29514418
[TBL] [Abstract][Full Text] [Related]
7. Off-Treatment Hepatitis B Virus (HBV) DNA Levels and the Prediction of Relapse After Discontinuation of Nucleos(t)ide Analogue Therapy in Patients With Chronic Hepatitis B: A Prospective Stop Study.
Cao J; Chi H; Yu T; Li Z; Hansen BE; Zhang X; Zhong C; Sun J; Hou J; Janssen HLA; Peng J
J Infect Dis; 2017 Feb; 215(4):581-589. PubMed ID: 28329347
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcomes and predictors for relapse after cessation of oral antiviral treatment in chronic hepatitis B patients.
Jung KS; Park JY; Chon YE; Kim HS; Kang W; Kim BK; Kim SU; Kim do Y; Han KH; Ahn SH
J Gastroenterol; 2016 Aug; 51(8):830-9. PubMed ID: 26687058
[TBL] [Abstract][Full Text] [Related]
9. Serum cytokine profiles predict outcomes of chronic hepatitis B patients discontinuing entecavir or tenofovir therapy.
Lin MJ; Su TH; Liu CJ; Yang HC; Chen CL; Liou JM; Tseng TC; Liu CH; Hong CM; Chen PJ; Kao JH
J Formos Med Assoc; 2023 Jul; 122(7):564-573. PubMed ID: 36872131
[TBL] [Abstract][Full Text] [Related]
10. Distinct Relapse Rates and Risk Predictors After Discontinuing Tenofovir and Entecavir Therapy.
Su TH; Yang HC; Tseng TC; Liou JM; Liu CH; Chen CL; Chen PJ; Chen DS; Liu CJ; Kao JH
J Infect Dis; 2018 Mar; 217(8):1193-1201. PubMed ID: 29300980
[TBL] [Abstract][Full Text] [Related]
11. HBeAg-positive patients with HBsAg < 100 IU/mL and negative HBV RNA have lower risk of virological relapse after nucleos(t)ide analogues cessation.
Xie Y; Li M; Ou X; Zheng S; Gao Y; Xu X; Yang Y; Ma A; Li J; Huang Y; Nan Y; Zheng H; Feng B
J Gastroenterol; 2021 Sep; 56(9):856-867. PubMed ID: 34292372
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis B relapse after entecavir or tenofovir alafenamide cessation under anti-viral prophylaxis for cancer chemotherapy.
Fang HW; Tseng PL; Hu TH; Wang JH; Hung CH; Lu SN; Chen CH
Virol J; 2024 Apr; 21(1):79. PubMed ID: 38570803
[TBL] [Abstract][Full Text] [Related]
13. Role of serum HBV RNA and hepatitis B surface antigen levels in identifying Asian patients with chronic hepatitis B suitable for entecavir cessation.
Seto WK; Liu KS; Mak LY; Cloherty G; Wong DK; Gersch J; Lam YF; Cheung KS; Chow N; Ko KL; To WP; Fung J; Yuen MF
Gut; 2021 Apr; 70(4):775-783. PubMed ID: 32759300
[TBL] [Abstract][Full Text] [Related]
14. HBV DNA and HBsAg Levels at 24 Weeks Off-Treatment Predict Clinical Relapse and HBsAg Loss in HBeAg-Negative Patients Who Discontinued Antiviral Therapy.
Sonneveld MJ; Chiu SM; Park JY; Brakenhoff SM; Kaewdech A; Seto WK; Tanaka Y; Carey I; Papatheodoridi M; Colombatto P; van Bömmel F; Janssen HL; Berg T; Zoulim F; Ahn SH; Dalekos GN; Erler NS; Brunetto M; Wedemeyer H; Cornberg M; Yuen MF; Agarwal K; Boonstra A; Buti M; Piratvisuth T; Papatheodoridis G; Chen CH; Maasoumy B;
Gastroenterology; 2024 Jan; 166(1):168-177.e8. PubMed ID: 37769952
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis B surface antigen titer is a good indicator of durable viral response after entecavir off-treatment for chronic hepatitis B.
Lee HA; Seo YS; Park SW; Park SJ; Kim TH; Suh SJ; Jung YK; Kim JH; An H; Yim HJ; Yeon JE; Byun KS; Um SH
Clin Mol Hepatol; 2016 Sep; 22(3):382-389. PubMed ID: 27729633
[TBL] [Abstract][Full Text] [Related]
16. Incidence and predictors of HBV relapse after cessation of nucleoside analogues in HBeAg-negative patients with HBsAg ≤ 200 IU/mL.
Yao CC; Hung CH; Hu TH; Lu SN; Wang JH; Lee CM; Chen CH
Sci Rep; 2017 May; 7(1):1839. PubMed ID: 28500322
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcome after cessation of nucleos(t)ide analog treatment in chronic hepatitis B patients who achieved HBsAg seroclearance.
Suzuki F; Hosaka T; Suzuki Y; Sezaki H; Akuta N; Fujiyama S; Kawamura Y; Saitoh S; Arase Y; Kobayashi M; Kumada H
J Gastroenterol; 2024 Jan; 59(1):34-44. PubMed ID: 37837569
[TBL] [Abstract][Full Text] [Related]
18. Improving the Prediction of Relapse After Nucleos(t)ide Analogue Discontinuation in Patients With Chronic Hepatitis B.
Song DS; Jang JW; Yoo SH; Kwon JH; Nam SW; Bae SH; Choi JY; Yoon SK
Clin Infect Dis; 2021 Aug; 73(4):e892-e903. PubMed ID: 33417679
[TBL] [Abstract][Full Text] [Related]
19. The role of hepatitis B virus core-related antigen in predicting hepatitis B virus relapse after cessation of entecavir in hepatitis B e antigen-negative patients.
Huang PY; Wang JH; Hung CH; Lu SN; Hu TH; Chen CH
J Viral Hepat; 2021 Aug; 28(8):1141-1149. PubMed ID: 33932245
[TBL] [Abstract][Full Text] [Related]
20. IP10 and Anti-HBc can Predict Virological Relapse and HBsAg Loss in Chronic Hepatitis B Patients after Nucleos(t)ide Analog Discontinuation.
Xie Y; Li M; Ou X; Zheng S; Gao Y; Xu X; Yang Y; Ma A; Li J; Nan Y; Zheng H; Liu J; Wei L; Feng B
Dig Dis; 2023; 41(6):922-931. PubMed ID: 37586356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]